In particular, the prolonged use of thiazolidinediones (TZDs), such as pioglitazone and rosiglitazone, which activate peroxisome proliferator-activated receptor gamma (PPARγ), has been associated with negative effects on bone metabolism, despite a beneficial effect on glycemic control (reduced insulin resistance and improved insulin sensitivity). Here, INS is linked to Insulin resistance.